



Bank of Maharashtra

AX1/ISD/STEX/28/2026-27

Date: 06.06.2026

The Vice President BSE Ltd., P.J Towers, Dalal Street, Mumbai-400 001	The Vice President National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai-400 051
BSE Scrip Code: 532525	NSE Scrip Code: MAHABANK

Dear Sir/ Madam,

Sub: Newspaper Publication – Intimation of Annual General Meeting

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find the enclosed copy of Newspaper publication about the intimation of 23rd Annual General Meeting of the Bank published in Financial Express (English Daily), Loksatta (Marathi Daily) and Jansatta (Hindi Daily).

Kindly take the same on record.

Thanking you.

Yours faithfully,

For Bank of Maharashtra

**(Vishal Sethia)
Company Secretary & Compliance Officer**

Encl: As above

Confidential

प्रधान कार्यालय / Head Office: "Lokmangal", 1501, Shivajinagar, Pune – 411005

कॉर्पोरेट कार्यालय / Corporate Office: 134/1, Mont Claire, Baner- Pashan Link Road, Pashan, Pune - 411021

टेली / Tel.: 020 71658139 ईमेल / Email: investor_services@bankofmaharashtra.bank.in वेबसाइट / Website: www.bankofmaharashtra.bank.in

Reliance Industries Limited
 Regd. office: 3rd Floor, Maker Chambers IV, 222, Nariman Point, Mumbai - 400 021.
 Phone: 022-3555 5000. Email: investorrelations@ril.com
 CIN: L17110MH1973PLC019786

NOTICE

NOTICE is hereby given that the following certificate(s) issued by the Company are stated to have been lost or misplaced and Registered Holders thereof have applied for the issue of duplicate certificate(s).

Sr. No.	Folio No.	Name / Joint Names	Shares	Certificate Nos. From - To	Distinctive Nos. From - To
1	9554271	Cherukara Thomas Mathew Mary Plathew Mrpc Jannadas Pahlajrai Gyanani	200	54790046-049	1327253620-819
			400	62650359-359	2221571087-486
			600	66854007-007	6892167077-676
			10	544591591	1740173-182
2	3745589	Jaykumar Jannadas Gyanani	14	1036146-416	25593148-161
			21	2201996-996	43471795-815
			5	3142904-904	49782443-447
			20	5055501-501	83302195-214
			30	6420741-741	135639638-667
			197	51675681-685	1187141517-713
			297	62435336-336	2205323558-854
			594	66486490-490	6878043278-871
			100	151148-149	8311178-277
			25	6826937-937	141693699-723
3	21548162	Satish R Nachnolkar	26	10309490-490	184834867-892
			31	12986163-163	260957659-689
			182	51663016-020	118662236-417
			364	62376792-792	2198602082-445
			20	4439367-367	71996639-658
			5	7544986-986	147505995-999
			10	10043232-232	18122552-561
			55	14782233-224	394439445-499
			90	5374206-208	1259181601-690
			180	62233593-593	218735425-425
360	66430521-521	6855534033-392			
Total			3836		

The Public is hereby cautioned against dealing with these shares in any way. Any person(s) who has / have any claim against these shares, should lodge such claim with the Company's Registrar and Transfer Agent viz. "K Fin Technologies Limited", Selenium Tower B, Plot No. 31-32, Gachibowli Financial District, Nanakramguda, Hyderabad - 500 032, within Seven (7) days from the date of publication of this notice, failing which, the Company will proceed to issue duplicate certificate(s) in respect of the aforesaid shares.

for Reliance Industries Limited
 Sd/-
 Savitri Parekh
 Company Secretary and Compliance Officer
 Place : Mumbai Date : June 5, 2026
 www.ril.com

INNOVA CAPTAB LIMITED
 CIN: L24246MH2005PLC150371
 Registered Office: 1513, 15th Floor, Satra Plaza, CHS Ltd. Plot No. 19 & 20, Sector-19D, Vashi, Navi Mumbai-400703, Maharashtra, India
 Phone: +91 22 6794 4000; Website: https://www.innovacaptab.com; Mail: investors@innovacaptab.com

NOTICE OF 22ND ANNUAL GENERAL MEETING OF THE COMPANY AND E-VOTING INFORMATION

NOTICE is hereby given that 22nd Annual General Meeting ("AGM") of Innova Captab Limited will be held through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") facility on **Monday, 29th June 2026 at 11:00 A.M. (IST)**, in compliance with applicable provisions of the Companies Act, 2013 and the Rules thereunder ("the Act"), and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended from time to time, read with applicable circulars issued by the Ministry of Corporate Affairs ("MCA Circulars") and the Securities and Exchange Board of India ("SEBI Circulars"), to transact the business set forth in the Notice convening the AGM ("Notice").

In compliance with the aforesaid MCA Circulars and the SEBI Circulars, Notice of AGM along with the Integrated Annual Report for FY 2025-26 has been sent electronically on 04th June 2026, to those Members whose e-mail addresses are registered with the Company or the Registrar and Share Transfer Agent ("RTA"), NSDL Database Management Limited or their respective Depositories Participants.

Further, in accordance with Regulation 36(1)(b) of SEBI Listing Regulations a letter providing the web-link, including the exact path/QR code for accessing the Integrated Annual Report is being sent to those members who have not registered their e-mail IDs.

The Notice of 22nd AGM and the Annual Report are also available on website(s) of the Company at www.innovacaptab.com, on website of the Stock Exchanges viz. BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on website of the e-voting agency viz. National Securities Depository Limited ("NSDL") at www.evoting.nsdl.com. The detailed procedure/ instructions for attending AGM, manner of casting vote through remote e-voting or through e-voting at the AGM is provided in the Notice of AGM.

In compliance with Section 108 of the Act, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Regulation 44 of the SEBI Listing Regulations and the Secretarial Standard on General Meetings (SS-2) issued by the Institute of Company Secretaries of India, the Members are provided with the facility to cast their votes on all resolutions set forth in the Notice of the AGM using electronic voting system (e-voting) provided by NSDL.

A person whose name is recorded in the Register of Members / Beneficial Owners as on the record date (**cut-off date**) i.e. **Monday, 22nd June, 2026**, shall only be entitled to avail the remote e-voting facility or vote at the AGM, as the case may be. The voting rights of Members shall be in proportion to the equity shares held by them in the paid-up equity share capital of the Company as on the cut-off date.

The remote e-voting facility will be available during the following voting period:

Commencement of remote e-Voting	Friday, 26th June, 2026 at 09:00 A.M. (IST)
End of remote e-Voting	Sunday, 28th June, 2026 at 05:00 P.M. (IST)

The e-voting module shall be disabled by NSDL thereafter and voting shall not be allowed beyond said time. Any person, who acquires shares and becomes a member of the Company after the dispatch of the notice and hold shares as on cut-off date i.e. **Monday, 22nd June, 2026**, may obtain login ID and password by sending a request at www.evoting.nsdl.com or investors@innovacaptab.com on to cast their vote electronically. However, if a person is already registered with NSDL for e-voting then the existing User ID and password can be used for casting their vote.

Manner of casting vote through e-voting and attending the AGM:

- Members will have an opportunity to cast their vote for the business as set forth in the notice of AGM through remote e-voting system as well as through e-voting during the AGM.
- Members who have cast their vote by remote e-voting prior to the AGM may attend the AGM through VC, but shall not be entitled to cast their vote again.
- The Login credentials for casting the votes through e-voting shall be made available to the Members through email after successful registering of their email addresses in the manner provided above.
- The same login credentials may also be used for attending the AGM through VC/OAVM.

Ms. Sandhya R Malhotra, Partner of M/s. Manish Ghia & Associates, Practicing Company Secretaries, Mumbai, have been appointed as the Scrutinizer for scrutinizing the e-voting process at the AGM in a fair and transparent manner. The results declared along with the Scrutinizer's Report within the prescribed period shall be displayed on the Company's website and shall also be communicated to BSE Limited and National Stock Exchange of India Limited.

The Members are requested to carefully read all the Notes set out in the Notice of the AGM and in particular, instructions for joining and attending the AGM through VC/OAVM, manner of casting vote through Remote e-voting and E-voting during the AGM.

In case of queries or grievances pertaining to e-voting procedure, members may refer the Frequently Asked Questions (FAQs) and e-voting manual available at www.evoting.nsdl.com or write and email to **Ms. Pallavi Mhatre, Assistant Vice President**, NSDL at evoting@nsdl.com or call on 022 - 4886 7000. Members may also write to the Company Secretary and Compliance Officer of the Company at investors@innovacaptab.com or at the Registered Office Address given above.

For Innova Captab Limited
 Sd/-
Neeharika Shukla
 Company Secretary
 and Compliance Officer
 Place : Panchkula Date : 06th June, 2026

NOVARTIS INDIA LIMITED
 CIN: L24200MH1947PLC006104
 Inspire BKC, 7th Floor, Bandra Kurla Complex Bandra East, Mumbai 400051 Maharashtra, India
 Tel.: +91 22 50243000; Website: www.novartis.in; Email: india.investors@novartis.com

Recommendations of the Committee of Independent Directors ("IDC") of Novartis India Limited ("Target Company") on the Open Offer for acquisition of up to 84,19,608 (Sixty Four Lakh Nineteen Thousand Six Hundred and Eight) fully paid-up equity shares having a face value of INR 5 (Indian Rupees Five) each ("Equity Shares") of the Target Company, representing 26% (Twenty Six per cent.) of the Voting Share Capital, from the Public Shareholders of the Target Company, by WaveRise Investments Limited ("Acquirer 1"), Chryscapital Fund X, the first scheme of Chryscapital Trust I, a category II alternative investment fund registered with SEBI ("Acquirer 2") and Two Infinity Partners ("Acquirer 3") (Acquirer 1, Acquirer 2 and Acquirer 3, collectively referred to as the "Acquirers"), along with Chryscapital X, LLC ("PAC 1") and OceanEdge Investments Limited ("PAC 2") (PAC 1 and PAC 2, collectively referred to as the "PACs"), in their capacity as persons acting in concert with the Acquirers for the purposes of the Open Offer, pursuant to and in compliance with the requirements of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto ("SEBI (SAST) Regulations") (the "Offer" / "Open Offer").

Sr. No.	Particulars	Details
1	Date	Thursday, June 04, 2026
2	Name of the Target Company	Novartis India Limited
3	Details of the Offer pertaining to Target Company	The Open Offer has been made by WaveRise Investments Limited, Chryscapital Fund X, the first scheme of Chryscapital Trust I and Two Infinity Partners, ("Acquirers") along with Chryscapital X, LLC and OceanEdge Investments Limited, being persons acting in concert ("PACs") along with the Acquirers, for acquisition of up to 84,19,608 fully paid-up equity shares having a face value of INR 5 each, representing 26% of the total voting share capital of the Target Company, at an offer price of INR 860.64 (Indian Rupees Eight Hundred Sixty and Sixty Four Paise) per equity share, pursuant to Regulations 3(1) and 4 of the SEBI (SAST) Regulations ("Offer Price"). The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the draft letter of offer filed with SEBI on March 5, 2026 ("DLOF") and the letter of offer filed with SEBI on June 01, 2026 ("LOF") have been issued by the Manager to the Open Offer on behalf of the Acquirers and the PACs. The Public Announcement in relation to the Open Offer was issued on February 19, 2026 by the Acquirers ("Public Announcement") pursuant to the Share Purchase Agreement dated February 19, 2026 entered into between the Acquirers and Novartis AG for acquisition of 1,74,50,680 equity shares representing 70.68% of the voting share capital of the Target Company and consequent acquisition of control over the Target Company ("Share Purchase Agreement"). The detailed public statement published on February 26, 2026, the

